Cardioprotection of vitexin on myocardial ischemia/reperfusion injury in rat via regulating inflammatory cytokines and MAPK pathway

Am J Chin Med. 2013;41(6):1251-66. doi: 10.1142/S0192415X13500845.

Abstract

This study was conducted to demonstrate myocardial protective effects and possible underlying mechanisms of vitexin on myocardial ischemia/reperfusion (I/R) injury in rats. Occluding the anterior descending artery for 30 min and restoring blood perfusion for 60 min in rat established a model of myocardial I/R. The elevation of the ST segment of Electrocardiograph (ECG) was observed. The infarct size of the rat heart was assessed by triphenyltetrazolium chloride staining (TTC). LDH, CK, SOD activities and MDA content were determined. An immunohistochemical analysis was applied to measure the expression of myocardial NF-κBp65 and TNF-α. ERK/phospho-ERKand c-Jun/phospho-c-Jun protein expression was examined via Western Blot. Vitexin significantly reduced the elevation of the ST segment of ECG and myocardial infarct size. LDH and CK activities and MDA content were attenuated in serum, while SOD activity was markedly enhanced. Vitexin significantly attenuated I/R-induced increases of myocardial NF-κB and TNF-α. Moreover, Western Blot analysis presented that vitexin markedly enhanced the expression of phospho-ERK and weakened the expression of phospho-c-Jun compared to I/R group. The significant protective effect against myocardial ischemical/reperfusion injury in rat, which is exhibited by vitexin, may be related to its antioxidative and anti-inflammatory effects by regulating inflammatory cytokines and the MAPK pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apigenin / administration & dosage*
  • Apigenin / pharmacology*
  • Cardiotonic Agents*
  • Cytokines / metabolism*
  • Disease Models, Animal
  • Down-Regulation
  • Electrocardiography
  • Gene Expression / drug effects
  • Inflammation Mediators / metabolism*
  • Infusions, Intravenous
  • MAP Kinase Signaling System / drug effects*
  • MAP Kinase Signaling System / genetics*
  • Male
  • Myocardial Ischemia / diagnosis*
  • Myocardial Ischemia / drug therapy*
  • Myocardial Ischemia / genetics
  • Myocardial Ischemia / pathology
  • Myocardial Reperfusion Injury / diagnosis*
  • Myocardial Reperfusion Injury / drug therapy*
  • Myocardial Reperfusion Injury / genetics
  • Myocardial Reperfusion Injury / pathology
  • Phytotherapy*
  • Proto-Oncogene Proteins c-jun / genetics
  • Proto-Oncogene Proteins c-jun / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Transcription Factor RelA / genetics
  • Transcription Factor RelA / metabolism
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / metabolism
  • Up-Regulation

Substances

  • Cardiotonic Agents
  • Cytokines
  • Inflammation Mediators
  • Proto-Oncogene Proteins c-jun
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • Apigenin
  • vitexin